Leading IVD manufacturer Helena Biosciences will be showcasing its industry first, non-invasive Glyco Liver Profile at the 2018 International Liver Congress in Paris, France this April (11th - 15th).
Visitors to stand 10F will be able to discover Helena Biosciences’ latest clinical application for liver disease diagnosis using glycomic biomarkers.
Developed by scientists at the VIB University of Ghent, Belgium, this test is the first of its kind delivering a comprehensive picture of chronic liver disease enabling clinicians to diagnose and monitor patients with hepatic inflammation, fibrosis and cirrhosis whilst providing a prognostic marker of HCC risk.
The test is conducted utilising capillary electrophoresis on Helena Biosciences’ V8 NEXUS analyser, with patient results displayed on Platinum 5 Touchscreen software.
Doctor Adam Stephenson, Director of Sales and Marketing at Helena Biosciences, said: “This is a huge year for the Glyco Liver Profile test and for Helena Biosciences. We have a brand new multi-analyte liver marker that has the potential to be a reference test in hospitals around the world.
“This is a truly innovative test utilising glycomic biomarkers to diagnose and predict the stage and prognosis of liver damage regardless of the aetiology. Given that we have a global installation base known for myeloma and thalassemia testing, this is one more powerful biomarker that we can roll out to the fleet.
As you can imagine, we are looking forward to sharing this technological advancement with those attending the International Liver Congress.”
For more information about Helena Biosciences or to learn more about the Glyco Liver Profile, please visit www.helena-biosciences.com/glp
To keep with up with the latest news you can follow Helena Biosciences on Twitter at www.twitter.com/HelenaBioSci or LinkedIn at www.linkedin.com/company/helena-biosciences-europe-limited
20 March 2018 10:16
Our Marketing department can help with your questions:
Telephone +44 (0)191 482 8440